ziprasidone

conclusion ziprasidone is a better drugs for the treatment of schizophrenia for its good efficacy and safety.

结论齐拉西酮是一种较理想的治疗精神分裂症的药物，其疗效确切，安全性较好，值得临床推广应用。

objective to compare the curative effect and safety of ziprasidone and quetiapine combined with perphenazine in treating schizophrenia.

目的比较齐拉西酮和奎硫平与奋乃静合并用药对精神分裂症的治疗效果和安全性。

a new generation of atypical antipsychotics: ziprasidone

新型非典型抗精神病药齐拉西酮

conclusion: ziprasidone treat women patients with schizophrenia, effective, not gain weight, fewer side effects, compliance.

结论：齐拉西酮治疗女性精神分裂症患者有效，不增加体重，不良反应少，依从性好。

objective: to understand ziprasidone treat women schizophrenia patients curative effect, weight change and compliance.

目的：了解齐拉西酮治疗女性精神分裂症患者疗效，体重变化及依从性。

Ziprasidone hydrochloride and its intermediate chemical structure by 1 H-NMR , MS, IR confirmed.

盐酸齐拉西酮及其中间体的化学结构经 1H-NMR 、 MS 、 IR确证.

Conclusion Ziprasidone has less influence on electrocardiogram and is safe in treatment of schizophrenia.

结论齐拉西酮对精神分裂症患者心电图的影响显著低于氯氮平.

abstract: objective to explore the clinical curative effect and security of ziprasidone and risperidone in the treatment of schizophrenia.

目的探讨齐拉西酮与利培酮相比治疗精神分裂症的临床疗效及安全性。

methods 66 patients with first-onset schizophrenia were randomly divided ziprasidone group and chlorpromazine group for 8 weeks.

方法将符合入组标准的首发精神分裂症病人66例随机分为齐拉西酮组与氯丙嗪组，系统治疗8周。

determination of ziprasidone hydrochloride and related substances by reversed-phase high performance liquid chromatography

反相高效液相色谱法测定盐酸齐拉西酮及有关物质

objective: to compare the efficacy and safety of ziprasidone and risperidone in treatment of schizophrenia.

目的：探讨齐拉西酮治疗首发精神分裂症患者的临床疗效及安全性。

objective to study the curative effect and side-effect of ziprasidone and quetiapine in treating patients with senile psychosis.

目的探讨齐拉西酮与奎硫平对老年性精神分裂症的疗效和不良反应。

methods: select 30 cases of female patients with schizophrenia, give ziprasidone treatment, treatment 8 weeks.

方法：选择30例女性精神分裂症患者，给予齐拉西酮治疗，疗程8周。

And the incidence rate of extrapyramidal symptoms was lower in ziprasidone group than in haloperidol group ( P < 0.05).

氟哌啶醇组锥体外系的发生率明显高于齐拉西酮组，差异有统计学意义（P<0.05）。

methods 72 cases of elderly patients with schizophrenia were randomly divided into ziprasidone group and per- phenazine group for 8 weeks.

方法将72例老年精神分裂症患者随机分为2组，分别给予齐拉西酮和奋乃静治疗8周。

conclusion ziprasidone in treatment of elderly schizophrenia is of good efficacy and relatively small adverse reactions.

结论齐拉西酮治疗老年精神分裂症患者疗效好，不良反应相对较小。

results: the concentration-time curves of ziprasidone fitted to two-compartment model.

结果：血药浓度-时间曲线为二室模型。

objectiveto evaluate the clinical curative effect and security of ziprasidone and risperidone in the treatment of schizophrenia.

目的：通过与利培酮的对比，评价齐拉西酮治疗精神分裂症的临床疗效及安全性。

conclusion ziprasidone is as effective as risperidone for treating schizophrenia with lower side effects.

结论齐拉西酮对精神分裂症患者的疗效与利培酮相当，副作用较小。

The incidence rate of adverse. 4 % in Ziprasidone group and .6 % in Aripiprazole group.

齐拉西酮组总不良反应发生率. 4%,阿立哌唑组总不良反应.6%.